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Abstract The role of Rac in epidermal growth factor (EGF)-
induced c-fos serum response element (SRE) activation was 
examined in Rat-2 fibroblast cells. By reporter gene analysis 
following transient or stable transfections with pEXV-RacN17 
encoding a dominant-negative mutant of Rac, EGF-induced 
activation of c-fos SRE-luciferase gene was shown to be 
selectively inhibited, suggesting that Rac activity is necessary 
for the full activation of SRE by EGF. Our further study to 
analyze the downstream mediator of Rac in EGF-signaling 
cascade demonstrated that there is a functional link between Rac 
and phospholipase A 2 (PLA2) activation and further that PLA 2 
mediates, at least partly, the Rac signaling to SRE. Together, 
our results point to a critical role of Rac and Rac-activated 
PLA 2 in the EGF-signaling cascade to c-fos SRE. We propose 
that 'Rac-PLA2' cascade is one of the major signaling pathways 
by which EGF stimulates c-fos SRE. 
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1. Introduction 
The c-fos serum response element (SRE) has been shown to 
be necessary and sufficient for the rapid induction of c-fos 
gene transcription in response to serum stimulation and is a 
primary nuclear target for many extracellular signals such as 
growth factors, cytokines, and environmental stress [1,2]. 
Whether these signals lead to c-fos SRE activation through 
independent or convergent pathways is not clearly under-
stood. A nuclear protein termed serum response factor 
(SRF) binds the C A r G box motifs, the inner core of SRE, 
present in the promoter regions of many immediate early 
genes including c-fos and several actins [1,3]. At the c-fos 
SRE, S R F forms a ternary complex with T C F (ternary com-
plex factor), which cannot bind the SRE by itself [2,4]. The 
Elk-1, one of TCFs , has been shown to regulate SRE in re-
sponse to activation of the R a s - R a f - E R K (extracellular sig-
nal-regulated protein kinases) cascade, known as M A P kinase 
pathway [2,5]. Recently, Rac and other Rho family GTPases 
have been shown to play a role in the signaling pathway to c-
fos SRE activation via M A P kinase-independent pathway 
which probably involves the direct activation of S R F [6]. 
Therefore, there is TCF/Elk-1-independent signaling pathway 
as well as TCF/Elk-1 -dependent pathway for the SRE activa-
tion [6]. 
*Corresponding author. Fax: (82) 361-53-1953. 
E-mail: jhkim@sun.hallym.ac.kr 
One of the immediate cellular responses to epidermal 
growth factor (EGF) is the transient transcription of c-fos 
via SRE [7]. Although R a s - R a f - E R K cascade represents the 
best-understood signaling pathway of E G F to c-fos SRE ac-
tivation, the role of Rac GTPase, a member of Rho family 
GTPases, has never been examined. Previously, an essential 
role of Rac has been suggested in the signaling cascade of 
E G F leading to actin remodeling, known as membrane ruf-
fling, or Ca 2 + influx [8-10]. For example, in Swiss 3T3 cells, 
Rac was shown to mediate EGF-induced arachidonic acid 
(AA) release via phospholipase A2 (PLA2) activation [8] and 
it has been reported that AA, a principal product of Rac-
activated PLA 2 , is implicated in EGF-induced actin remodel-
ing or stimulation of Ca 2 + influx [9,10]. This connection be-
tween E G F and Rac activation therefore raises the possibility 
that Rac may also play an important role in the nuclear sig-
naling by E G F . 
In this study, we examined whether Rac GTPase activity is 
necessary for EGF-induced c-fos SRE activation in Rat-2 fi-
broblast cells. Our results showed that Rac activity and Rac-
activated PLA 2 are critical for EGF-induced c-fos SRE acti-
vation. Therefore, ' R a c - P L A 2 - A A ' cascade could be regarded 
as one of the major signaling pathways by which E G F stim-
ulates c-fos SRE. 
2. Materials and methods 
2.1. Chemicals and plasmids 
Arachidonic acid, mepacrine, and lysophosphatidic acid (LPA) 
were obtained from Sigma Chemical Co. (St. Louis, MO). Epidermal 
growth factor (EGF) was purchased from Boehringer-Mannheim 
GmbH (Mannheim, Germany). All other chemicals were from stand-
ard sources and were molecular biology grade or higher. The pSRE-
Luc was derived from pFos-lcf [11] and it contains sequences —53 to 
+45 of the c-fos promoter upstream of the luciferase coding sequences 
with c-fos SRE oligonucleotide inserted at the —53 position. pEXV 
and pEXV-RacN17 plasmids were gifts from Dr. A. Hall. pEXV-
RhoN19 plasmid was constructed by subcloning RhoAN19 fragment 
into EcoRI site of pEXV vector. All Rac, Rho, Ras proteins were 
expressed as N-terminally 9E10 epitope-tagged derivatives under 
SV40 promoter. 
2.2. Cell lines and cultures 
Rat-2 fibroblast cells were obtained from the American Type Cul-
ture Collection (ATCC, CRL 1764). Rat-2 stable clones expressing 
RacN17 were prepared by co-transfecting pEXV-RacN17 with pSV-
NeoR plasmid followed by selecting the clones in the presence of 
G418 antibiotics (400 ug/ml) for 2-3 weeks. Expression of RacN17 
protein in the representative clone was confirmed by Western hybrid-
ization using anti-myc epitope antibody. 
2.3. Transfections and luciferase assay 
Transient transfection analysis was performed by calcium phos-
phate: DNA precipitation method [3,12]. To control for variations 
in both cell numbers and transfection efficiency, all clones were co-
transfected with 1 ug of pCMV-ßGAL, an eucaryotic expression vec-
tor in which E. coli ß-galactosidase (lacZ) structural gene is under the 
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Fig. 1. A: Diagram of pSRE-luciferase reporter gene plasmid. The structure of construct containing SRE oligonucleotide sequences (23mers) in-
serted to —53 position of the truncated c-fos promoter fused to luciferase gene is shown. B (left): Dose-dependent SRE activation by EGF. 
Various concentrations of EGF (0, 25, 50, 100, 200 ng/ml) were treated for 2 h to the transfected cells with pSRE-Luc (3 |ig) plasmid. 
B (right): Time-dependent response of EGF (50 ng/ml) on SRE activation. Serum-starved, transfected Rat-2 cells were treated with EGF for 
the lengths of time indicated. Luciferase activities were measured as described in Section 2. 
transcriptional control of the CMV promoter. Lysates prepared from 
the harvested cells were assayed for both luciferase activity and ß-
galactosidase activity, which was used as an internal standard to nor-
malize the luciferase activity directed by the test plasmid. Luciferase 
activity was determined as described previously [13,14]. Transfection 
experiments were performed in triplicate with two independently iso-
lated sets, and the results were averaged. 
2.4. [3HJArachidonic acid release 
Rat-2 or Rat2-RacN17 cells in DMEM medium containing 10% 
fetal bovine serum (FBS) were plated to 1 X 105 cells per well (12 
well plate). Three hours later, 0.5 liCi/ml of [3H]AA (250 itCi; Amer-
sham) was supplemented to each well and incubated for 24 h, then 
washed at least 4 times with DMEM containing 0.5% FBS. Then, cells 
were labeled with [3H]AA at 0.5 iiCi/ml for 48 h in DMEM/0.5% 
FBS, washed 8 times with DMEM/0.5% FBS, and finally added 
with 2 ml of DMEM/0.5% FBS containing EGF (50 ng/ml) or control 
buffer for 1-2 h. The released [3H]AA into the medium was quanti-
tated by scintillation counting of 0.5 ml of medium each time. At the 
end of experiments, the cells were solubilized with 0.5 ml of ethyl 
alcohol (EtOH) for the determination of total intracellular incorpo-
ration. Counts were corrected for total incorporation. 
3. Results and discussion 
3.1. EGF-induced SRE activation is inhibited by a dominant 
negative mutant, RacN17 
To determine the SRE-stimulating activity by EGF, we 
carried out transient transfection analysis using a reporter 
plasmid, pSRE-Luc, containing c-fos SRE fused to luciferase 
coding sequences, described in Fig. 1A. Following transient 
transfection, Rat-2 cells were serum-starved in DMEM con-
taining 0.5% FBS for 36 h before the addition of EGF. SRE 
activation was monitored by luciferase activities normalized 
with co-transfected ß-galactosidase activity. As shown in Fig. 
1, EGF stimulated the promoter activity of c-fos SRE in a 
dose- and time-dependent manner. By dose-responsive analy-
sis, maximal luciferase activity was reached at 50 ng/ml con-
centration of EGF (Fig. IB). Also, by time-dependent analy-
sis, a 6-fold increase in the luciferase activity occurred 2 h 
after the addition of EGF and by 6 h, the c-fos SRE luciferase 
level declined. 
To examine any contributing role of Rac GTPase in the 
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Fig. 2. A: Inhibition of EGF-induced SRE activation by RacN17. A reporter gene plasmid, pSRE-Luc (3 (xg) was transiently co-transfected 
with 5 ug of pEXV, RasN17, RacN17, or RhoN19 to Rat-2 cells. Total amounts of DNA was kept at 20 ug with calf thymus carrier DNA. 
Transfected cells were serum-deprived for 36 h before EGF (50 ng/ml) or LPA (10 uM) treatment. After 2 h of treatment, luciferase activities 
were measured and the relative luciferase activities were calculated. B: Rat-2 expressing RacN17 (Rat2-RacN17) shows relative inhibition to 
EGF-induced SRE activation. Following transfection with pSRE-Luc plasmid (3 |xg), Rat-2 and Rat2-RacN17 cells were serum-starved in 
DMEM containing 0.5% FBS for 36 h before treating control buffer (-), EGF (50 ng/ml), LPA (10 uM), or AA (100 uM). After 2 h of treat-
ment, SRE activation was monitored by luciferase activities normalized with co-transfected ß-galactosidase activity. 
EGF-induced SRE activation, pSRE-Luc (3 |xg) was transi-
ently co-transfected with 5 ug of pEXV (control vector) or 
pEXV-RacN17 encoding a dominant negative mutant of 
Racl. As shown in Fig. 2A, EGF-induced SRE activation is 
significantly inhibited by co-transfection with pEXV-RacN17 
( « 40% reduction of luciferase activity), suggesting that Rac 
activity is necessary for the full activation of SRE by EGF. A 
more drastic inhibition was observed (60% reduction of luci-
ferase activity) by co-transfection with pEXV-RasN17 encod-
ing a dominant negative H-Ras. In contrast, no detectable 
inhibition was observed by co-transfection with pEXV-
RhoN19 encoding a dominant negative RhoA (Fig. 2A). On 
the other hand, lysophosphatidic acid (LPA)-induced SRE 
activation was dramatically inhibited only by RhoN19, not 
by RasN17 or RacN17, indicating that LPA signaling to c-
fos SRE is primarily through Rho-linked pathway (Fig. 2A). 
This result is in well agreement with the previous report show-
ing that LPA activates c-fos SRE principally via Rho-depend-
ent pathway [6]. Together, these results suggest that EGF-
induced SRE activation requires Rac as well as Ras activity 
in Rat-2 fibroblast cells. 
To further investigate the role of Rac in EGF-induced SRE 
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Fig. 3. PLA2 is necessary for the full activation of SRE by EGF. A: Rat-2 cells were transiently transfected with 3 u.g of pSRE-Luc plasmid 
and then serum-starved for 36 h in DMEM medium containing 0.5% FBS. Mepacrine (1 uM) was pretreated 30 min before the addition of 
control buffer (—), EGF (50 ng/ml) or LPA (10 uM). At 2 h later, luciferase activities were measured and normalized with ß-galactosidase ac-
tivities. B: A reporter gene plasmid, pSRE-Luc (3 ug) was transiently co-transfected with 2.5 ug of pcDNA3 (empty vector) or pcDNA3-LCl, 
a lipocortin-1 expression plasmid. Total amounts of DNA was kept at 20 |ig with calf thymus carrier DNA. Transfected cells were serum-de-
prived in DMEM with 0.5% FBS for 36 h before addition of control buffer (-), EGF (50 ng/ml) or LPA (10 uM). At 2 h later, luciferase ac-
tivities were measured and normalized with ß-galactosidase activities. Values were representative of multiple transfections. 
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Fig. 4. Rac-activated PLA2 mediates the release of [3H]AA in a mepacrine-sensitive manner. A: Rat-2 cells were labeled with [3H]AA (0.5 |xCi/ 
ml; 48 h) and washed 8 times with DMEM/0.5% FBS as described in Section 2. Mepacrine (1 uM) was pretreated 30 min before the addition 
of control buffer (—) or EGF (50 ng/ml). At 2 h later, the released [3H]AA into the medium was quantitated by scintillation counting. B:Rat-2 
and Rat2-RacN17 cells were labeled with [3H]AA and washed as same as above. Control buffer or EGF (50 ng/ml) was added 2 h before the 
harvest for determination of [3H]AA release. The released [3H]AA into the medium was quantitated by scintillation counting and normalized 
by the total counts as described in Section 2. 
activation, we prepared Rat-2 stable cells expressing RacN17 
as described in Section 2. Following transient transfection 
with pSRE-Luc plasmid, Rat-2 and Rat2-RacN17 cells were 
serum-starved in DMEM containing 0.5% FBS for 36 h be-
fore treating EGF, LPA, or AA. As shown in Fig. 2B, in 
Rat2-RacN17 cells, EGF-induced SRE activation was signifi-
cantly inhibited up to 50% level of that in Rat-2 parental cells. 
On the other hand, the addition of either LPA or AA, a 
principal product of PLA2, induced the same level of SRE 
stimulation in Rat-2 and Rat2-RacN17 cells, respectively 
(Fig. 2B). From these and earlier results (Fig. 2A), we con-
clude that EGF signaling to c-fos SRE is, at least partly, 
mediated by Rac-linked pathway. 
3.2. PLAi activity is necessary for EGF-induced SRE 
activation 
Recently, AA was shown to be released via Rac activation 
in response to EGF, implying a potential role of 'Rac-acti-
vated PLA2 and subsequent AA release' in the signaling path-
way of EGF leading to actin remodeling [8]. In a further study 
to understand the downstream element of Rac in EGF-signal-
ing pathway leading to c-fos SRE, we examined any possible 
role of PLA2 as a downstream mediator of Rac in this signal-
ing cascade. As an initial approach toward this study, we first 
determined whether PLA2 activity is necessary for EGF-in-
duced c-fos SRE activation. To do this, we tested the effect 
of mepacrine, a potent inhibitor of PLA2, on the EGF-in-
duced SRE activation. Rat-2 cells were transiently transfected 
with pSRE-Luc, followed by EGF (50 ng/ml) or LPA (10 uM) 
treatment. The SRE activation was monitored by luciferase 
activities, normalized with co-transfected ß-galactosidase ac-
tivity. As shown in Fig. 3A, mepacrine (1 u,M) inhibited EGF-
induced SRE activation significantly ( ~ 50% inhibition of lu-
ciferase activity) without affecting LPA-induced SRE activa-
tion, suggesting a specific role of PLA2 activity in EGF-signal-
ing cascade to c-fos SRE. 
To obtain further insight into the role of PLA2 in EGF 
signaling to SRE, we have examined whether EGF-induced 
SRE activation is sensitive to other type of PLA2 inhibitor. 
For this analysis, lipocortin-1 [15], which is also called annex-
in-1, expression was used. Lipocortin-1 has been shown to 
specifically inhibit PLA2 via still-unknown mechanism in var-
ious cases [15-17]. Cells were transiently co-transfected with 
pcDNA3 (vector) or pcDNA3-LCl (lipocortin-1), and deter-
mined whether lipocortin-1 transfection could block the EGF-
induced SRE activation. We observed that by pcDNA3-LCl 
co-transfection, EGF-induced SRE activation was signifi-
cantly inhibited (50% reduction of luciferase activity) whereas 
LPA-induced SRE activation was not affected (Fig. 3B). 
These results again indicate that the signaling pathway of 
EGF to c-fos SRE is partly dependent upon functional 
PLA2 activity. 
3.3. Role of 'Rac-activated PLA2' in EGF-signaling cascade 
Although the above results suggest a critical role of PLA2 
in EGF-signaling cascade to c-fos SRE, it still does not give 
any evidence regarding the role of Rac in the activation of 
PLA2, thus we cannot exclude the possibility that EGF-in-
duced PLA2 activation may result from alternative routes in-
dependent of Rac. To demonstrate the functional existence of 
'Rac-activated PLA2' as downstream element of Rac in EGF 
signaling to SRE, we examined if EGF-induced PLA2 activa-
tion is mediated mainly through Rac. To do this, we first 
determined to measure AA liberation in response to EGF 
treatment to Rat-2 cells which had been pre-labeled with 
[3H] AA as described in Section 2. As shown in Fig. 4A, 
EGF induced a significant liberation of AA ( =s 40% stimula-
tion of AA release over control), but, this over-induced liber-
ation of AA was completely diminished by 30 min pretreat-
ment of mepacrine (1 uM), suggesting that PLA2 mediates 
EGF-induced AA release (Fig. 4A). Next, we determined 
whether this PLA2-mediated AA liberation requires Rac ac-
tivity. By comparing the level of AA liberation in between 
Rat-2 and Rat-2 stable cells expressing RacN17 (Rat2-
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Fig. 5. RacV12 co-transfection activates SRE in a mepacrine-sensitive manner. A: Transient co-transfection of pEXV-RacV12 (5 ug) with 3 (tg 
of either pO-Luc (vector without SRE insert) or pSRE-Luc. The relative activation of pSREwt-Luc to pO-Luc promoter activity was calculated 
and histograms of the results of the luciferase are shown. Values were representative of multiple transfections. B: Inhibition of RacV12-induced 
SRE activation by mepacrine. A reporter gene plasmid, pSRE-Luc (3 |xg) was transiently co-transfected with 5 |ig of pEXV, RacV12, or 
RhoV14 to Rat-2 cells. Total amounts of DNA was kept at 20 iig with calf thymus carrier DNA. Transfected cells were serum-deprived for 30 
h before treatment of various concentration of mepacrine (0, 0.5, 1.0, 2.0 |iM). At 6 h later, luciferase activities were measured as described in 
Section 2. The relative activity was calculated as percentage (%) activity of the control (without mepacrine treatment). 
RacN17), it was shown that EGF-induced AA liberation is 
fully dependent on Rac activity (Fig. 4B). Taken together, 
these results indicate that the EGF-induced AA liberation is 
through PLA2 activation and further that this PLA2 activa-
tion is mediated mainly through Rac. Thus, Rac-activated 
PLA2 is suggested to mediate EGF-induced AA release. 
To gain further evidence for the functional link between 
Rac and PLA2 in EGF-signaling cascade to c-fos SRE acti-
vation, we undertook the analysis of Rac-induced activity to 
stimulate SRE and examined whether PLA2 activity is re-
quired for Rac-induced SRE activation. In agreement with 
the proposed role as an important mediator of EGF signaling 
to c-fos SRE, co-transfection of Rac-expression plasmid is 
sufficient to stimulate the SRE-linked promoter activity via 
Ras/MAP kinase-independent pathway (data not shown). 
pEXV-RacV12 encoding a constitutively active GTPase-defi-
cient allele of Racl, termed RacV12 was transiently co-trans-
fected with a reporter plasmid, pO-Luc (a control vector with-
out SRE) or pSRE-Luc. As shown in Fig. 5A, by pEXV-
RacV12 (5 |xg) co-transfection, a remarkable stimulation 
( ~ 35-fold) of the relative activity of pSRE-luciferase to pO-
luciferase was observed. Next, we determined whether 
RacV12-induced SRE activation is mediated by PLA2. To 
do this, pSRE-Luc (3 u,g) was transiently co-transfected with 
5 ug of pEXV, pEXV-RacV12, or pEXV-RhoV14 to Rat-2 
cells. Transfected cells were serum-deprived in DMEM con-
taining 0.5% FBS for 30 h before the treatment of various 
concentration of mepacrine (0.5, 1.0, 2.0 U.M). As shown in 
Fig. 5B, mepacrine exhibited a dose-dependent inhibition on 
the RacV12-induced SRE stimulation, not on RhoV14-in-
duced SRE activation. At 2.0 |iM concentration of mepacrine 
pretreatment, RacV12-induced SRE stimulation was reduced 
up to 50% level of control whereas RhoV14-induced activa-
tion of SRE was not affected (Fig. 5B). This result indicates 
that Rac-signaling cascade leading to c-fos SRE activation is 
significantly mediated via PLA2 activation which will induce 
the release of AA. 
In the present study, our results provide evidence for a 
critical role of Rac in EGF-induced activation of c-fos SRE 
in Rat-2 fibroblast cells. Although the detail mechanism of 
Rac action in EGF signaling to SRE remains unclear yet, 
our results indicate that the action of Rac is exerted, at least 
partly, through the activation of PLA2 in Rat-2 fibroblasts. 
Therefore, Rac and Rac-activated PLA2 clearly participate in 
the signaling pathway from EGF to c-fos SRE in nucleus. 
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